HHS Peptide Compounding Update: What Patients and Providers Should Know

Westmoreland Peptide Compounding

HHS Peptide Compounding Update: What Patients and Providers Should Know

October 30, 2026

 

A recent announcement from the U.S. Department of Health and Human Services (HHS) could change access to certain compounded peptides. It also raises important questions about ingredient sourcing, testing, prescribing, and patient safety. 

At Westmoreland Pharmacy, we are following guidance from the Alliance for Pharmacy Compounding (APC) as these developments unfold. Our approach centers on understanding the requirements, evaluating ingredient quality, and keeping patients and healthcare providers informed. 

The most important point: this announcement is not FDA approval of these peptides, and it does not necessarily mean they are immediately available. 

What Did HHS Announce?

HHS announced an interim enforcement-discretion policy addressing six peptide ingredients used in 503A compounding. Section 503A generally applies to medications prepared by licensed pharmacies or physicians for individual patients based on valid prescriptions.

“Enforcement discretion” means HHS does not intend to take enforcement action for using the specified ingredients when the policy’s conditions are satisfied, while FDA works through the formal process of determining their eligibility for compounding.

According to APC, this policy does not:

  • Make these peptides FDA-approved drugs.
  • Add them to the 503A Bulks List or Category 1 list.
  • Authorize research-grade ingredients for human treatment.
  • Remove existing prescription requirements or state pharmacy oversight.

Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before they are marketed.

Which Six Peptides Are Included?

Peptides are short chains of amino acids, the building blocks of proteins. They can play different roles in biological processes. The HHS policy identifies the following six substances, with specific chemical forms and routes of administration addressed in its appendices.

BPC-157

BPC-157 is a synthetic peptide composed of 15 amino acids. It is frequently discussed in research involving tissue responses to injury and gastrointestinal health.

Epitalon

Epitalon, also spelled epithalon, is a synthetic four-amino-acid peptide. Researchers have investigated its effects on cellular processes and age-related biology.

KPV

KPV is a three-amino-acid peptide consisting of lysine, proline, and valine. Its name comes from the abbreviations for those amino acids. It is related to a fragment of alpha-melanocyte-stimulating hormone and has been investigated in inflammation-related research.

MOTS-c

MOTS-c is a 16-amino-acid peptide associated with mitochondria, the structures involved in cellular energy production. Researchers have studied its role in metabolic signaling and cellular responses to stress.

Semax

Semax is a synthetic seven-amino-acid peptide modeled on a fragment of adrenocorticotropic hormone, or ACTH. It has been investigated for effects involving the nervous system. The HHS policy specifies intranasal use for the identified form.

TB-500

The TB-500 identified in the HHS policy is a seven-amino-acid fragment related to thymosin beta-4, a protein involved in cellular processes. It should not be confused with the full-length thymosin beta-4 protein; evidence involving one cannot automatically be applied to the other.

None of these six peptides are FDA-approved. Evidence and remaining uncertainties differ among them. Inclusion in an enforcement policy does not establish that a peptide is appropriate for any particular patient.

Why APC Says the Safeguards Matter

APC’s October 28 statement welcomes a more accountable pathway for peptide compounding while emphasizing that access must come with meaningful safeguards.

A central concern is the use of peptides obtained outside the regulated healthcare system, including products labeled “research use only.” Those products are not an appropriate substitute for prescription medications prepared under pharmacy oversight.

The HHS policy includes requirements addressing:

  • Ingredient sourcing: The original active-ingredient manufacturer must be FDA-registered and meet applicable manufacturing requirements.
  • Documented testing: Certificates of analysis must support ingredient identity, purity, potency, and appropriate contaminant testing.
  • Traceability: Records must identify the manufacturer and the ingredient batch.
  • Single-active-ingredient preparations: The policy does not permit peptide blends or combinations with other active pharmaceutical ingredients.
  • Patient-specific prescriptions: A valid prescription remains necessary.
  • Safety reporting: Serious adverse events and product-quality concerns must be reported.
  • Formulation limitations: Specific routes apply, and oral formulations require documentation supporting adequate absorption in humans.

These requirements involve much more than purchasing an ingredient and beginning to compound. 

Why Availability May Take Time

APC cautions that suppliers must demonstrate that their ingredients meet the policy’s extensive requirements. Pharmacies must then verify the supporting documentation. 

In its initial statement, APC also identified questions requiring clarification, including when the policy takes effect, how testing documentation will be validated, how reporting will work, and how implementation will coordinate with state boards of pharmacy. 

Westmoreland Pharmacy is following APC’s guidance as these questions are addressed. This update is educational and is not an announcement that all six peptides are available from our pharmacy. 

Westmoreland’s Commitment to Quality

When considering any compounded prescription, patients and prescribers should ask about the pharmacy’s credentials, personnel, quality systems, and communication.

Westmoreland Pharmacy brings several established strengths to that conversation:

PCAB Accreditation Through ACHC

Westmoreland is accredited by the Pharmacy Compounding Accreditation Board (PCAB) through the Accreditation Commission for Health Care (ACHC). This accreditation reflects an external assessment of compounding practices against defined quality standards.

Board-Certified Pharmacists

Westmoreland has five staff pharmacists who are Board Certified Sterile Compounding Pharmacists. This specialized credential reflects additional expertise relevant to sterile preparation and medication quality.

Quality Testing

Westmoreland’s quality program includes rigorous testing appropriate to each compounded preparation, including potency, sterility, and endotoxin testing, as applicable. Any peptide preparation considered under the proposed HHS policy would also be carefully evaluated to ensure compliance with its specific ingredient sourcing, documentation, testing, and formulation requirements.

Collaboration With Prescribers

Our pharmacists work with healthcare providers to review individual prescription needs and answer formulation questions. Patient care includes clear communication about appropriate use, storage, monitoring, and concerns that should be discussed with the prescriber.

These qualifications support accountable pharmacy practice. They do not make a compounded medication FDA-approved or eliminate the uncertainties associated with an investigational ingredient.

 

Have Questions About the Peptide Update?

Start with your healthcare provider and one of our licensed compounding pharmacists. Ask about the evidence, potential risks, ingredient sourcing, testing, and whether an option is appropriate for your individual medical needs.

Westmoreland Pharmacy will continue monitoring HHS developments and APC guidance and sharing updates as implementation becomes clearer. We will be offering educational opportunities for our providers, including prescribing guidelines.

Contact our pharmacy team at 812-944-6500 with questions about this announcement or our compounding quality standards.

This information reflects documents available as of October 29, 2026. Requirements and availability may change. A valid prescription is required for compounded prescription medications.

The policy interpretation follows the attached APC statement and HHS policy:

Westmoreland’s accreditation, pharmacist credentials, and testing statements are supported by our website. Peptide definitions also draw on FDA materials and published research.